Trilink’s Stock mRNA’s with CleanCap®

TriLink BioTechnologies

A part of Maravai LifeSciences, TriLink is a best-in-class contract development and manufacturing organization helping life science leaders and innovators overcome challenges in the synthesis and scale-up of nucleic acids, NTPs and mRNA capping analogs with scale-up expertise and unique mRNA production capabilities, including its proprietary CleanCap® mRNA capping technology. TriLink continues to expand its cGMP and general mRNA, oligonucleotide & plasmid manufacturing capacity at its new global headquarters to support therapeutic, vaccine and diagnostic customers.

CleanCap Technology

In cells, the ribosome translates mRNA into proteins. mRNA in eukaryotic cells has either a 5′ Cap 1 or Cap 2 [m7G(5′)ppp(5′)G] structure which stabilizes the mRNA and enhances translation. A cap can be incorporated in the mRNA transcription by including a mixture of cap analog and NTPs. Greater than 90% of transcribed mRNA will possess a 5′ cap, while the remaining mRNA will possess a 5′ triphosphate. In some cases it is desirable to remove the 5′ triphosphate with a phosphatase treatment.

TriLink’s CleanCap analog enables high capping efficiencies (90%+) resulting in more biologically active mRNA per transcription. It also produces a natural Cap 1 structure. Efficient translation of the mRNA into protein also requires a poly(A) tail. This can be efficiently introduced by including a poly(dT) stretch at the end of the transcription template. This can also be accomplished by an additional post-transcription PCR step that utilizes a primer containing the poly(dT) stretch.

Click to View Products